

CHANGE - ANNOUNCEMENT OF CESSATION::RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

Issuer & Securities

Issuer/ Manager

BIOLIDICS LIMITED

Securities

BIOLIDICS LIMITED - SGXE89830751 - 8YY

Stapled Security

No

Announcement Details

Announcement Title

Change - Announcement of Cessation

Date & Time of Broadcast

14-Jun-2024 22:09:01

Status

New

Announcement Sub Title

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

Announcement Reference

SG240614OTHRSMGA

Submitted By (Co./ Ind. Name)

Zhu Hua

Designation

Executive Director and Chairman

Description (Please provide a detailed description of the event in the box below)

Resignation of Mr Song Tang Yih ("Mr Song") as an Executive Director and Chief Executive Officer ("CEO") of Biolidics Limited (the "Company").

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "Sponsor") for compliance with relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST").

This announcement has not been examined or approved by the SGX-ST, and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are: -

Name: Mr. Jerry Chua (Registered Professional, Evolve Capital Advisory Private Limited) and Mr. Tan Jun Yong (Registered Professional, Evolve Capital Advisory Private Limited)
Address :138 Robinson Road, Oxley Tower, #13-02, Singapore 068906
Tel :(65) 6241 6626

Additional Details

Name Of Person

Song Tang Yih

Age

60

Is effective date of cessation known?

Yes

If yes, please provide the date

30/06/2024

Detailed Reason (s) for cessation

To pursue other career opportunities.

The Sponsor, after having interviewed Mr Song, is satisfied that save as disclosed in this announcement, there is no other material reason for the resignation of Mr Song as an Executive Director and CEO of the Company.

Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?

No

Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?

No

Any other relevant information to be provided to shareholders of the listed issuer?

No

Date of Appointment to current position

01/09/2021

Does the AC have a minimum of 3 members (taking into account this cessation)?

Yes

Number of Independent Directors currently resident in Singapore (taking into account this cessation)

2

Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months

2

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Executive Director and Chief Executive Officer

Role and responsibilities

Mr Song is responsible for the overall management, operations, strategic planning and business development of the Group.

Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries

None

Shareholding interest in the listed issuer and its subsidiaries?

Yes

Shareholding Details

24,501,500 shares in the Company

Past (for the last 5 years)

1. ClearCell Pte. Ltd.
 2. Biomedics Laboratory Pte. Ltd.
-

Present

1. Drukpa Singapore Limited
-